Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph plus ALL: a Children's Oncology Group (COG) study

被引：33

作者：

Chang, Bill H. ^{[1
,2
]}

Willis, Stephanie G. ^{[3
]}

Stork, Linda ^{[1
,2
]}

Hunger, Stephen P. ^{[4
]}

Carroll, William L. ^{[5
]}

Camitta, Bruce M. ^{[6
,7
]}

Winick, Naomi J. ^{[8
]}

Druker, Brian J. ^{[3
,9
]}

Schultz, Kirk R. ^{[10
,11
]}

机构：

[1] Oregon Hlth & Sci Univ, Dept Pediat, Div Pediat Hematol & Oncol, Portland, OR 97201 USA

[2] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Portland, OR 97201 USA

[3] Oregon Hlth & Sci Univ, OHSU Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA

[4] Univ Colorado, Sch Med, Childrens Hosp Colorado, Div Pediat Hematol,BMT, Aurora, CO USA

[5] NYU, Med Ctr, Inst Canc, New York, NY 10016 USA

[6] Childrens Hosp Wisconsin, Midwest Ctr Canc & Blood Disorders, Milwaukee, WI 53201 USA

[7] Med Coll Wisconsin, Milwaukee, WI 53226 USA

[8] Univ Texas SW Med Ctr Dallas, Dept Pediat Hematol Oncol, Dallas, TX 75390 USA

[9] Howard Hughes Med Ctr, Portland, OR USA

[10] Univ British Columbia, Pediat Hematol Oncol BMT, Vancouver, BC V5Z 1M9, Canada

[11] BC Childrens Hosp, Vancouver, BC, Canada

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 157卷 / 04期

关键词：

leukaemia; BCR-ABL1; mutations; childhood; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; PHILADELPHIA-CHROMOSOME; KINASE; INHIBITORS; THERAPY;

D O I：

10.1111/j.1365-2141.2012.09039.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：507 / 510

页数：4

共 9 条

[1] Clinical Outcome of Children With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005 [J].

Arico, Maurizio ;

Schrappe, Martin ;

Hunger, Stephen P. ;

Carroll, William L. ;

Conter, Valentino ;

Galimberti, Stefania ;

Manabe, Atsushi ;

Saha, Vaskar ;

Baruchel, Andre ;

Vettenranta, Kim ;

Horibe, Keizo ;

Benoit, Yves ;

Pieters, Rob ;

Escherich, Gabriele ;

Silverman, Lewis B. ;

Pui, Ching-Hon ;

Valsecchi, Maria Grazia .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (31) :4755-4761

[2] Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia [J].

Boulos, Nidal ;

Mulder, Heather L. ;

Calabrese, Christopher R. ;

Morrison, Jeffrey B. ;

Rehg, Jerold E. ;

Relling, Mary V. ;

Sherr, Charles J. ;

Williams, Richard T. .

BLOOD, 2011, 117 (13) :3585-3595

[3] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].

Druker, BJ ;

Sawyers, CL ;

Kantarjian, H ;

Resta, DJ ;

Reese, SF ;

Ford, JM ;

Capdeville, R ;

Talpaz, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042

[4] Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia [J].

Hu, YG ;

Liu, YH ;

Pelletier, S ;

Buchdunger, E ;

Warmuth, M ;

Fabbro, D ;

Hallek, M ;

Van Etten, RA ;

Li, SG .

NATURE GENETICS, 2004, 36 (05) :453-461

[5] Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors [J].

Jones, Dan ;

Thomas, Deborah ;

Yin, C. Cameron ;

O'Brien, Susan ;

Cortes, Jorge E. ;

Jabbour, Elias ;

Breeden, Megan ;

Giles, Francis J. ;

Zhao, Weiqiang ;

Kantarjian, Hagop M. .

CANCER, 2008, 113 (05) :985-994

[6] In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants [J].

O'Hare, T ;

Walters, DK ;

Stoffregen, EP ;

Jia, TP ;

Manley, PW ;

Mestan, J ;

Cowan-Jacob, SW ;

Lee, FY ;

Heinrich, MC ;

Deininger, MWN ;

Druker, BJ .

CANCER RESEARCH, 2005, 65 (11) :4500-4505

[7] Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) [J].

Pfeifer, Heike ;

Wassmann, Barbara ;

Pavlova, Anna ;

Wunderle, Lydia ;

Oldenburg, Johannes ;

Binckebanck, Anja ;

Lange, Thoralf ;

Hochhaus, Andreas ;

Wystub, Silvia ;

Brueck, Patrick ;

Hoelzer, Dieter ;

Ottmann, Oliver G. .

BLOOD, 2007, 110 (02) :727-734

[8] First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia [J].

Ravandi, Farhad ;

O'Brien, Susan ;

Thomas, Deborah ;

Faderl, Stefan ;

Jones, Dan ;

Garris, Rebecca ;

Dara, Samuel ;

Jorgensen, Jeffrey ;

Kebriaei, Partow ;

Champlin, Richard ;

Borthakur, Gautam ;

Burger, Jan ;

Ferrajoli, Alessandra ;

Garcia-Manero, Guillermo ;

Wierda, William ;

Cortes, Jorge ;

Kantarjian, Hagop .

BLOOD, 2010, 116 (12) :2070-2077

[9] Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study [J].

Schultz, Kirk R. ;

Bowman, W. Paul ;

Aledo, Alexander ;

Slayton, William B. ;

Sather, Harland ;

Devidas, Meenakshi ;

Wang, Chenguang ;

Davies, Stella M. ;

Gaynon, Paul S. ;

Trigg, Michael ;

Rutledge, Robert ;

Burden, Laura ;

Jorstad, Dean ;

Carroll, Andrew ;

Heerema, Nyla A. ;

Winick, Naomi ;

Borowitz, Michael J. ;

Hunger, Stephen P. ;

Carroll, William L. ;

Camitta, Bruce .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (31) :5175-5181

← 1 →